Navigation Links
Xanodyne Announces Planned President & CEO Succession
Date:5/27/2010

NEWPORT, Ky., May 27 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. is pleased to announce that Natasha Giordano has been named to the position of President and Chief Executive Officer and will be elected to the Company's Board of Directors, succeeding Michael J. Valentino.

The management transition was planned by the Board and follows a year of significant new product and commercial successes under Mr. Valentino's leadership.  In 2009, Xanodyne received FDA approval for Zipsor®, a new treatment option indicated for relief of mild to moderate acute pain in adults.  The Company also received FDA approval for Lysteda™ indicated for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.  Recently, Xanodyne announced that is has tightly focused the strategic direction for the company on the pain management market, and the related sale of Lysteda™ to Ferring Pharmaceuticals.  Xanodyne has a strategic partnership with Ferring for the co-promotion of Zipsor®.

Ms. Giordano most recently served as the company's Chief Operating Officer during this period of unprecedented success.  Ms. Giordano has more than 25 years of experience in the healthcare and pharmaceutical industry and prior to Xanodyne served as President Americas at Cegedim Dendrite, a global sales and marketing solutions and information company specializing in the pharmaceutical industry.  Her depth of experience includes senior leadership positions in general management, marketing, compliance, and sales at major pharmaceutical companies including Pfizer and Parke-Davis.

Ms. Giordano said, "I look forward to working with the Board and management team in continuing to drive toward our vision of being a leader in the pain management category.  We have a proven track record of bringing innovative products to the market, and developing strategic partnerships where desired,  as well as the people, resources and strategy to focus Xanodyne on high growth opportunities within the pain franchise."

Mr. Valentino said, "I am very pleased to be leaving Xanodyne with high caliber talent on the management team, and throughout the organization.  Natasha's knowledge of the industry and her continued strong leadership will sustain the momentum as Xanodyne focuses its growth in pain management. The successful launch of Zipsor®, the portfolio of legacy brands, and strategic divestiture of non-core assets, including Lysteda™, position Xanodyne well for the future."

Rolf Classon, Chairman of the Board said, "We are very pleased with this planned leadership succession.  Mike expanded his Board responsibility to include the CEO role last year with the intent of seeing our drugs through approval and commercialization, and building a team to refine the strategic direction of the business.  The successful partnership between Mike and Natasha allows us a smooth senior management transition as we move forward and execute against our strategic priorities. On behalf of myself and the Board, I'd like to thank Mike for his contributions to the Board and for his stewardship of the Company during this crucial year. "

About Xanodyne Pharmaceuticals, Inc.

Xanodyne, which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused exclusively on pain management. Xanodyne markets a portfolio of products consisting of prescription pain management pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing its pipeline of product candidates targeted at significant potential segments of the pain management market including chronic and severe pain. For more information visit www.Xanodyne.com.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
2. Xanodyne Announces Renewed Focus on Pain Management Market
3. Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
4. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
5. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
6. China Yongxin Pharmaceuticals Announces 1-for-12 Reverse Stock Split
7. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
8. Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
9. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
10. FDA Announces Collaboration With Drugs.com
11. VisEn Announces New ProSense® 750 FAST and Neutrophil Elastase™ 680 FAST Fluorescence Molecular Imaging Agents at European Molecular Imaging Meeting 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
Breaking Medicine News(10 mins):